Asprosin-driven metabolic-epigenetic rewiring attenuates mesenchymal stem cell senescence with therapeutic benefits for infarcted hearts

Key Points

Asprosin rejuvenates mesenchymal stem cells, counteracting senescence effectively.
This metabolic-epigenetic interplay showcases the potential for regenerative therapies targeting heart diseases.
The study emphasizes the 'Glycolysis-Lactylation-Epigenetics' axis as a transformative strategy in treatment.
Findings indicate that enhancing asprosin pathways may lead to significant therapeutic advancements.

Abstract

Asprosin is a novel MSC-specific rejuvenation factor that antagonizes senescence through metabolic-epigenetic interplay. Targeting the asprosin-driven "Glycolysis-Lactylation-Epigenetics" axis offers a transformative strategy to enhance MSC-based therapies for ischemic heart disease.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Zhang et al. (Thu,) studied this question.

synapsesocial.com/papers/69a75eb3c6e9836116a298fe https://doi.org/https://doi.org/10.1016/j.jare.2026.01.073

Bookmark

View Full Paper